340B
Covered entity and grantee program operation, contract pharmacy oversight, split-billing and mixed-use configuration, and audit readiness.
About
Robert Walters, PharmD, MBA
Founder, Walters Rx Strategy. Apexus Advanced 340B Certified. Fifteen years in health-system pharmacy leadership across 340B, oncology infusion, specialty pharmacy, formulary management, and P&T committee work.
Background
I spent fifteen years leading pharmacy operations inside a New Jersey health system, most recently as Senior Director of Pharmacy and Oncology Infusion. My teams covered acute care, the cancer center, infusion, and emergency department pharmacy across a multi-site system: roughly a hundred people, a nine-figure drug-spend portfolio, and one of the larger 340B programs in the region.
That work came with the full regulatory weight: 340B audits, wholesaler conversions in the middle of a workflow crisis, DEA inspections with zero findings, and New Jersey Board of Pharmacy surveys with no deficiencies cited. I also know the quiet cost of doing nothing: the reimbursement that leaks, the audit exposure that compounds, and the patients who wait longer for therapy while everyone waits for permission to fix it.
Walters Rx Strategy is built for leaders who need outcomes, not slide decks: 340B compliance and optimization, oncology and specialty pharmacy access, patient access and reimbursement strategy, and formulary and P&T guidance. You get a colleague in the room who has actually run the thing.
Apexus Advanced 340B Certified | MBA
Areas of practice
Where the fifteen years actually applies.
Oncology and infusion
Cancer center and infusion pharmacy operations, regimen and pathway implementation, chair-time and capacity management, and charge capture.
Specialty pharmacy
Network and limited-distribution access, referral-to-fill capture, accreditation, and the operating model underneath all of it.
Formulary and P&T
Formulary process design, committee structure and evidence standards, biosimilar and therapeutic interchange, and high-cost drug governance.
Patient access and reimbursement
Benefits investigation, prior authorization, patient assistance and foundation navigation, and the analytics that show where patients fall out.
Regulatory and operations
USP 797 and 800, DEA and board of pharmacy readiness, DSCSA, diversion program design, and wholesaler conversion.
Work with me
Consulting inquiries and manufacturer or partner inquiries both start with a short call.